Limits...
Effect of transdermal estrogen therapy on bone mineral density in postmenopausal korean women.

Kim HJ, Oh YK, Lee JS, Lee DY, Choi D, Yoon BK - J Menopausal Med (2014)

Bottom Line: Demographic profiles and changes in BMD over two years were compared according to the route of the estrogen.No differences were found in age, age at menopause, parity, body mass index, and type of menopause among the oral, transdermal and control groups.Transdermal estrogen therapy increases BMD, comparable to oral estrogen, in postmenopausal Korean women.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics, Gynecology and Women's Health, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Objectives: To evaluate the effects of transdermal estrogen therapy on bone mineral density (BMD) in postmenopausal Korean women.

Methods: A total of 149 healthy postmenopausal women were retrospectively evaluated: 100 were on hormone therapy (HT) and 49 were the control group. For the HT group, 54 applied estrogen transdermally using either a patch (n = 21) or gel (n = 33), and 46 took estrogen orally (conjugated estrogen 0.625 mg or equivalent). Demographic profiles and changes in BMD over two years were compared according to the route of the estrogen.

Results: No differences were found in age, age at menopause, parity, body mass index, and type of menopause among the oral, transdermal and control groups. Compared with controls, HT significantly increased BMD after 2 years in both the lumbar spine and the total hip. The increases in BMD at both lumbar spine and hip were comparable between the oral and transdermal groups. There were also no differences in BMD changes according to progestogen addition in either the oral or transdermal groups.

Conclusion: Transdermal estrogen therapy increases BMD, comparable to oral estrogen, in postmenopausal Korean women.

No MeSH data available.


Changes in bone mineral density in women taking estrogen-alone according to route of administration. TD: transdermal.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4286655&req=5

Figure 2: Changes in bone mineral density in women taking estrogen-alone according to route of administration. TD: transdermal.

Mentions: In women who received estrogen alone (n = 31), the changes of BMD were not significantly different between the oral (n = 16) and tarnsdermal (n = 15) orute (Fig. 2).


Effect of transdermal estrogen therapy on bone mineral density in postmenopausal korean women.

Kim HJ, Oh YK, Lee JS, Lee DY, Choi D, Yoon BK - J Menopausal Med (2014)

Changes in bone mineral density in women taking estrogen-alone according to route of administration. TD: transdermal.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4286655&req=5

Figure 2: Changes in bone mineral density in women taking estrogen-alone according to route of administration. TD: transdermal.
Mentions: In women who received estrogen alone (n = 31), the changes of BMD were not significantly different between the oral (n = 16) and tarnsdermal (n = 15) orute (Fig. 2).

Bottom Line: Demographic profiles and changes in BMD over two years were compared according to the route of the estrogen.No differences were found in age, age at menopause, parity, body mass index, and type of menopause among the oral, transdermal and control groups.Transdermal estrogen therapy increases BMD, comparable to oral estrogen, in postmenopausal Korean women.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics, Gynecology and Women's Health, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Objectives: To evaluate the effects of transdermal estrogen therapy on bone mineral density (BMD) in postmenopausal Korean women.

Methods: A total of 149 healthy postmenopausal women were retrospectively evaluated: 100 were on hormone therapy (HT) and 49 were the control group. For the HT group, 54 applied estrogen transdermally using either a patch (n = 21) or gel (n = 33), and 46 took estrogen orally (conjugated estrogen 0.625 mg or equivalent). Demographic profiles and changes in BMD over two years were compared according to the route of the estrogen.

Results: No differences were found in age, age at menopause, parity, body mass index, and type of menopause among the oral, transdermal and control groups. Compared with controls, HT significantly increased BMD after 2 years in both the lumbar spine and the total hip. The increases in BMD at both lumbar spine and hip were comparable between the oral and transdermal groups. There were also no differences in BMD changes according to progestogen addition in either the oral or transdermal groups.

Conclusion: Transdermal estrogen therapy increases BMD, comparable to oral estrogen, in postmenopausal Korean women.

No MeSH data available.